![Immunovant, Inc. logo](/logos/IMVT.webp)
Immunovant, Inc.
NASDAQ:IMVT
Overview | Financials
Company Name | Immunovant, Inc. |
Symbol | IMVT |
Currency | USD |
Price | 34.03 |
Market Cap | 4,980,869,010 |
Dividend Yield | 0% |
52-week-range | 19.5 - 45.58 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Peter Salzmann M.B.A., M.D. |
Website | https://immunovant.com |
An error occurred while fetching data.
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD